Citi 12 th Annual Biotech Conference September 7, 2017
|
|
- Dwain Garrett
- 6 years ago
- Views:
Transcription
1 Citi 12 th Annual Biotech Conference September 7, 2017
2 Safe harbor statement Certain information, particularly information relating to future performance and other business matters, including expectations regarding clinical development, market opportunities and anticipated milestones constitute forwardlooking statements within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements may generally contain words such as believe, may, could, will, possible, can, estimate, continue, ongoing, consider, intend, plan, project, expect, should, would, or assume or variations of such words or other words with similar meanings. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time and may cause actual results to differ materially from the results discussed in the forward-looking statements. Uncertainties include but are not limited to clinical trial results, dependence on third party contractors, competition for clinical resources and patient enrollment and risks that we may lack the financial resources to fund ongoing operations. Additional information on Risk Factors are contained in Novavax filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which are available at Forward-looking statements are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. Current results may not be predictive of future results. You should not place undue reliance on forward-looking statements which speak only as of the date hereof. The Company does not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law. 2
3 Novavax Targets: Influenza and RSV, the leading causes of respiratory tract infection RSV RSV remains a major unmet medical need in both children and older adults and a vaccine is an ideal solution Novavax is the leader in RSV vaccine development Novavax RSV F Vaccine is a multi-billion dollar revenue opportunity Influenza (Flu) Efficacy of seasonal flu vaccines is inconsistent and rarely better than 50% 1 Annual flu vaccination is universally recommended due to large burden of disease Novavax is targeting a better, differentiated flu vaccine Flu vaccine market was approximately $3.1B in 2015 in the 7 major markets 2, major markets: USA, Japan, Italy, Spain, UK, Germany and France 3 PharmaPoint Seasonal Influenza Vaccines Global Drug Forecast and Market Analysis to 2025, October
4 ` RSV F Vaccine Phase 3 Trial Infants via Maternal Immunization
5 Novavax Phase 3 RSV F Vaccine For Infants Via Maternal Immunization Addresses Significant Unmet Medical Need RSV is the most common cause of lower respiratory tract infections among young children RSV is the leading cause of hospitalization among children <1 year old in the United States 2,3 Globally, RSV is second only to malaria as a cause of death in children <1 year old 4 $89 million Bill and Melinda Gates Foundation grant supports the Prepare trial, addresses Foundation mission of childhood mortality RSV is largely a disease of healthy, full-term infants The smaller airways and immature immune systems of infants make them more susceptible to severe disease Natural immunity, derived from the mother, is relatively ineffective, and would benefit from a maternal vaccine 1. Nair H et al. Lancet. 2010;375: Munoz FM. Curr Opin Infect Dis. 2015;28: Leader SL, Kohlhase K. Pediatr Infect Dis J. 2002;21(7): Oxford Vaccine Group. Vaccine Knowledge Project. Respiratory syncytial virus (RSV). May 11, Accessed July 23,
6 Maternal Immunization: Building on a Proven Strategy Building on Proven Strategy Growing acceptance of maternal vaccination for flu and pertussis among HCPs and mothers American College of Obstetrics and Gynecology conducts CME-accredited webinar: Respiratory Syncytial Virus: The Need for a Maternal Immunization Strategy Vaccine Injury Compensation Program (VICP) Amendment in 21st Century Cures Act: As of December 13, 2016, program covers both a woman who received a covered vaccine while pregnant and any child who was in utero under government no-fault insurance program ACIP RSV Working Group CDC Advisory Committee on Immunization Practices (ACIP) established RSV Working Group, May 2016 First step towards ACIP consideration for recommendation RESCEU (REspiratory Syncytial virus Consortium in EUrope) EU consortium of global leaders in RSV research (academia, public policy, industry) Epidemiology, surveillance and economic burden research 6
7 Novavax Has Conducted a Number of Successful Phase 2 Trials with RSV F Vaccine Women of child-bearing age Safety and immunogenicity confirmed in dose selection trials Demonstration of ~50% reduction of RSV infections in vaccine groups in two trials in two separate seasons Pregnant women Vaccine was well-tolerated Response to RSV F Vaccine in pregnant women replicated immune response in non-pregnant women Anti-F, PCA, and neutralizing transplacental antibody transfer confirmed Observed half-life of ~40 days for MN and PCA through first 60 days post delivery Suggests protection of infants for up to 180 days 7
8 Phase 3 RSV F Vaccine for Infants via Maternal Immunization Trial: Goals and Design Primary Objective Design Determine the efficacy of maternal immunization with the RSV F Vaccine against symptomatic RSV lower respiratory tract infection (LRTI) with objective measures of medical significance of LRTI through the first 90 days of life in infants. Randomized, Observer-Blind, Placebo-Controlled, Group Sequential Number of participants Global Sites Length of Participation Minimum 4,600 women Year 3: US, Mexico, Chile, Argentina, UK, Spain, South Africa, Australia, New Zealand, Philippines, India Maternal Participants: 9 months Infant Participants: 1 year 1 IM Injection (RSV F Vaccine or Placebo), weeks EGA 8
9 The Phase 3 Prepare Trial has Entered its Third Year Global infrastructure has been established to drive enrollment and surveillance Recruitment and surveillance are going well and indicate trial feasibility Global Season 1: 16 sites in 5 countries Global Season 2: 46 sites in 7 countries Global Season 3: 80 sites in 11 countries Argentina Australia Chile India Mexico New Zealand Philippines South Africa Spain United Kingdom United States 9
10 Protecting Infants from RSV via Maternal Immunization Global footprint has grown from 16 sites in 5 countries in first season of enrollment to 80 sites in 11 countries in third season Interim analysis occurs at 4,600 vaccinees Requires a minimum of 3,000 vaccinees Expect to trigger unblinding in 2018 Novavax has the only vaccine in clinical trials for maternal immunization 10
11 Annual burden of RSV disease in infants 0-6 months of 1.9m infections affects those most at risk Potential U.S. market: ~4 million pregnancies/year ~34,000 Hospital Admissions 2 ~109,000 ER Visits 2 1.9M Infections 1 ~263,000 Outpatient Visits 2 ~31 Deaths 3 Values represent estimated annual rates. 1 CDC National Vital Statistics Birth Cohort Data; 2 Hall et al., NEJM 2009; 3 McLaurin et al., J Perinatol
12 ` Nanoparticle influenza vaccine with Matrix-M (NanoFlu) 12
13 Influenza (Flu) Market is Large, and Growing, with Little Product Differentiation Effectiveness of current licensed flu vaccines is inconsistent, and in some years, not effective at all Pricing is generally commodity-like, the exception being Fluzone HD and, recently, FluAd, both for the older adult market Novavax is targeting a high-value, differentiable product Product timelines create very near-term value: Phase 1/2 immunogenicity data in 330 older adults against market leader FDA End Of Phase 2 meeting Potential for accelerated approval (precedent: Fluzone HD, FluAd, Flulaval) Dec 2017 Jan 2018 Initiate pivotal phase 3 trial Sep 2018 Phase 3 data readout Dec 2018 BLA filing 4Q
14 NanoFlu Target Product Profile Point of Market Entry Immunogenicity Profile Broadly Neutralizing Capability Older Adults (65 years and older) HAI and Microneutralization titers equal to (or better than) the best-selling vaccine in older adults (Fluzone High Dose) Better neutralization against drifted strains Effectiveness Superior protection over Fluzone High Dose Manufacturing High yields High purity Stable Recombinant, egg-free 14
15 Percent Effectiveness A Significant Percentage of Older Adults get Vaccinated for Influenza Current influenza immunization rates in North America: Vaccination rate Year USA (U.S. CDC) 66.7% 2014/15 Canada (Statistics Canada) % 2014 Total (pop. wt. avg.) 66.4% CDC aims to have at least 90% of adults aged 65 or older receive an annual flu shot by Effectiveness of Licensed Flu Vaccines All Ages Older Adults * ** Source: 1 Statistics Canada: x/ /article/14218-eng.htm; Bonten, M.J.M. et al. Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults. NEJM, 2015; 372: * Pandemic H1N1 season ** 14% for dominant H3N2 15
16 Influenza Vaccine Market Landscape Approximately $3.1B in 2015 in the 7 major markets 1,2 Growing to $4.3B by EU5 market is expected to grow by 70% and reaching almost $1B in sales by Current average influenza vaccination rate of older adults in EU5 is 57% Strong growth since 2005/ ACIP recommendation for universal vaccination in U.S. 3 US remains the largest market with ~59% of major market sales 2 Source: 1 7 major markets: USA, Japan, Italy, Spain, UK, Germany and France 2 PharmaPoint Seasonal Influenza Vaccines Global Drug Forecast and Market Analysis to 2025, October ECDC 2012/3 Survey: 16
17 Novavax Nanoparticle Influenza Vaccine candidate (NanoFlu) Novavax NanoFlu preclinical data demonstrate a superior, differentiated immunogenicity and efficacy profile based on those established models and markers, potentially addressing deficiencies of current flu vaccines Flu has established preclinical models and surrogate immunogenicity markers that are reasonably likely to predict clinical benefit We expect to have Phase 1/2 human safety and immunogenicity data by year-end which will drive discussions with BARDA and potential partners Plan for 1Q 2018 end of phase 2 FDA meeting, could lead to near-term pivotal Phase 3 immunogenicity trial 17
18 Influenza Virus - Primary Vaccine Target: Hemagglutinin Receptor binding region is the target for antibodies that prevent virus binding to cells. These antibodies are highly strainspecific and dominate the immune response. HA Protein Structure Antibodies to receptor binding site can be detected by hemagglutination inhibition (HAI) Hemagglutination inhibiting antibodies are established surrogate markers of protection from influenza that could be the basis for licensure 18
19 Flu Program Data Published in Vaccine Full publication is available on Novavax website or at: 19
20 Preclinical Study Design - Ferret Immunogenicity & Challenge Study Group Immunization Blood Draw Virus Challenge Influenza A/H3N2 Placebo NanoFlu 15µg/HA + 50µg Matrix Fluzone HD 60µg/HA Fluzone 15µg/HA Days 0 and 21 Days 21 and 42 Day 49 Challenge Virus in Ferret Model A H3N2: current strain, matched to vaccine A H3N2: 10-yr. old strain, unmatched to vaccine 20
21 Ferret Immunogenicity & Challenge Study Novavax NanoFlu Fluzone HD Fluzone Quadrivalent A/Michigan (H1N1) A/California (H1N1) A/HongKong (H3N2) B/Brisbane B/Phuket 21
22 H A I T i t e r H A I T i t e r s H A I T i t e r H A I T i t e r Immunogenicity: NanoFlu Induced Superior Hemagglutination Inhibition (HAI) Day 42 Antibody Responses A/Michigan (H1N1) A / M i c h i g a n / 4 5 / A/California (H1N1) A / C a l i f o r n i a / 0 7 / L O D L O D 2 P l a c e b o NanoFlu N I V + Matrix M + M a t r i x - M 1 F l u z o n e H D F l u z o n e 2 P l a c e b o NanoFlu N I V + + M a t r i x Matrix M F l u z o n e H D F l u z o n e A / H o n g K o n g / / A/Hong Kong (H3N2) B/Brisbane B / B r i s b a n e / 6 0 / L O D L O D 2 4 P l a c e b o N I V NanoFlu + Matrix M + M a t r i x M F l u z o n e H D F l u z o n e 2 P l a c e b o NanoFlu N I V + Matrix + M a t r i x M F l u z o n e H D F l u z o n e 22
23 H A I T i t e r H A I T i t e r s H A I T i t e r H A I T i t e r Immunogenicity: NanoFlu Induced Superior Hemagglutination Inhibition (HAI) Day 42 Antibody Responses A/Michigan (H1N1) A / M i c h i g a n / 4 5 / A/California (H1N1) A / C a l i f o r n i a / 0 7 / L O D L O D 2 P l a c e b o NanoFlu N I V + Matrix M + M a t r i x - M 1 F l u z o n e H D F l u z o n e 2 P l a c e b o NanoFlu N I V + + M a t r i x Matrix M F l u z o n e H D F l u z o n e A/Hong Kong (H3N2) A / H o n g K o n g / / B/Brisbane B / B r i s b a n e / 6 0 / L O D 8 4 L O D 2 P l a c e b o NanoFlu N I V + Matrix M + M a t r i x M F l u z o n e H D F l u z o n e 2 P l a c e b o NanoFlu N I V + + M a t r i x Matrix M F l u z o n e H D F l u z o n e 23
24 50% MN Titers (Log 2 ) 50% MN Titers (Log 2 ) 50% MN Titers (Log 2 ) 50% MN Titers (Log 2 ) Immunogenicity: NanoFlu Induced Superior Microneutralizing (MN) Day 42 Antibody Responses A/Michigan (H1N1) A/California (H1N1) NanoFlu + Matrix M NanoFlu + Matrix M A/Hong Kong (H3N2) B/Brisbane NanoFlu + Matrix M NanoFlu + Matrix M 24
25 50% MN Titers (Log 2 ) 50% MN Titers (Log 2 ) 50% MN Titers (Log 2 ) 50% MN Titers (Log 2 ) Immunogenicity: NanoFlu Induced Superior Microneutralizing (MN) Day 42 Antibody Responses A/Michigan (H1N1) A/California (H1N1) NanoFlu + Matrix M NanoFlu + Matrix M A/Hong Kong (H3N2) B/Brisbane NanoFlu + Matrix M NanoFlu + Matrix M 25
26 Immunogenicity: NanoFlu Vaccine Induced Broadly Neutralizing Antibodies against Drifted A(H3N2) Influenza Viruses 5 0 % M N T i t e r s ( L o g 2 ) NNanoFlu I V + M + a Matrix t r i x M M FFluzone l u z o n e HD H D Fluzone F l u z o n e Q I V A / H o n g K o n g / / 1 4 A / S w i t z e r l a n d / / 1 3 A / T e x a s / 5 0 / 1 2 A / V i c t o r i a / / 1 1 A / P e r t h / 1 6 / 0 9 A / B r i s b a n e / 1 0 / 0 7 A / W i s c o n s i n / 6 7 / 0 5 A / N e w Y o r k / 5 5 / 0 4 A / F u j i a n / / 0 2 A / P a n a m a / 0 7 /
27 N a s a l W a s h V ir u s T ite r (L o g 1 0 p fu /m L ) N a s a l W a s h V ir u s T ite r (L o g 1 0 p fu /m L ) NanoFlu Vaccine was Superior in Protecting Ferrets Challenged with Matched and 10-year Drifted H3N2 (unmatched) Strain A/Hong Kong/4801/2014 (H3N2) like A /H o n g K o n g / / (H 3 N 2 ) A/Alaska/140/2015 (matched) A /A la s k a /1 4 0 / A/Brisbane/10/2007 (H3N2)-like A/Texas/71/2007 (unmatched) A /B ris b a n e /1 0 / )H 3 N 2 )-lik e A /T e x a s /7 1 / NanoFlu vs placebo p < NanoFlu vs placebo p < NanoFlu vs Fluzone HD p < NanoFlu vs Fluzone p < NanoFlu vs Fluzone HD p < NanoFlu vs Fluzone p < LO Q LO Q D a y P o s t-c h a lle n g e D a y P o s t-c h a lle n g e NanoFlu + Matrix M Placebo c e b o N IV + M a trix -M FFluzone z o n e HHD D FFluzone z o n e n=5 for each group Statistics were longitudinal (repeat measure) analysis performed by including Days 2, 4 and 6. Day 8 was excluded because all animals came back down to baseline 27
28 NanoFlu Product Development Strategy Seasonal, older adult vaccine candidate in head-to-head trial 4Q 2017: Data from Phase 1/2 trial designed to show product differences from current market leader 1Q 2018: End of Phase 2 meeting expected, potential for accelerated approval 4Q 2018: Pivotal immunogenicity data 2019: Followed by lot consistency trials and BLA filing Potential for funding with an industry partner and/or HHS-BARDA NanoFlu platform meets goals targeted by HHS-BARDA Potential for funding of seasonal and pandemic vaccines BARDA: Biomedical Advanced Research and Development Authority 28
29 ` RSV F Vaccine in Older Adults (E205)
30 Recently Announced E-205 Vaccine/Adjuvant Study Conclusions Adjuvant effects The adjuvants meaningfully increased immunity in measures generally associated with effective immunity Anti-F and PCA MN titers Avidity of antibodies to neutralizing epitopes Memory B cell and CD4+ T cells specific for F protein Durability of the responses are important and are improved with 2 doses The totality of the immune effects makes use of the adjuvants desirable and likely to de-risk the next steps Both classic and new immune measures build our confidence that these are better formulations to use in the next steps With respect to safety: All adjuvanted formulations were clinically tolerable 30
31 Path Forward for Older Adult Vaccine Building on E-205 data, RSV F Vaccine will be formulated with adjuvant for older adults Two pathways to licensure: 1. Conduct a Phase 2 efficacy trial in a highly susceptible population A profound vaccine effect was demonstrated in both our Phase 2 and Phase 3 trial in older adults w/ COPD, and/or, 2. Conduct a pivotal trial in all older adults Trial design to mimic Phase 3 maternal immunization, event-driven, multiple season trial with adjuvant formulation Initiation dependent upon status of NanoFlu development 31
32 Impact of Vaccine on COPD Exacerbations Post-hoc Analyses of Hospitalizations for All Cause COPD Exacerbations in E-201 and E-301 Data from the Safety Database E301 Day Placebo Vaccine VE% 95% CI p value COPD hospitalization rate in all subjects COPD hospitalization rate in subjects with baseline COPD E 201 Day COPD hospitalization rate in all subjects COPD hospitalization rate in subjects with baseline COPD 23/5935 (0.39%) 9/5921 (0.15%) 60.8% /362 (4.1%) 9/403 (2.2%) 46.1% /801 (0.50%) 0/798 (0%) 100% NC NC 2/62 (3.2%) 0/58 (0%) 100% NC NC After Day 182 (i.e., after the winter-spring RSV season) the effect on COPD exacerbation essentially disappears in E-301 After Day 182, an effect appears to continue in E
33 Proportion of Population Free of COPD Exacerbation COPD Hospitalizations in E All-Cause COPD Exacerbation Hospitalization-Free Survival in E Active Placebo Days From Treatment 33
34 Summary of COPD Opportunity A significant market opportunity exists with COPD, ~ $1.5 billion globally Prevention of acute exacerbations of COPD with the RSV F Vaccine would have a significant impact on the clinical and economic burden of COPD in the United States 1. Centers for Disease Control and Prevention. MMWR. Employment and Activity Limitations Among Adults with Chronic Obstructive Pulmonary Disease United States, March 27, Accessed July 21, Wilkinson TMA et al. Thorax. Published Online first 2017 Apr 21; doi: /thoraxjnl Qureshi H et al. Ther Adv Chronic Dis. 2014;5(5):
35 Upcoming Flu and RSV Milestones Novavax is the leader in RSV vaccine development Phase 3 program for RSV maternal immunization supported by Bill & Melinda Gates Foundation grant of $89 million Interim data analysis in 2018 Differentiated NanoFlu program Data from Phase 1/2 trial in 4Q 2017 End Of Phase 2 FDA meeting 1Q 2018 NanoFlu pivotal Phase 3 data 4Q
J.P. Morgan Healthcare Conference January 2018
` J.P. Morgan Healthcare Conference January 2018 Safe harbor statement Certain information, particularly information relating to future performance and other business matters, including expectations regarding
More informationCorporate Update. April 2018 NASDAQ:NVAX Novavax, Inc. All rights reserved.
Corporate Update April 2018 2018 Novavax, Inc. All rights reserved. NASDAQ:NVAX Safe harbor statement Certain information, particularly information relating to future performance and other business matters,
More informationNASDAQ:NVAX Novavax, Inc. All rights reserved.
Novavax vaccine induced improved immune responses against homologous and drifted A(H3N2) viruses in older adults compared to egg-based, high-dose, influenza vaccine World Vaccine Congress April 4, 2018
More informationDevelopment of Recombinant MERS-CoV Spike (S) Nanoparticle Vaccine
Development of Recombinant MERS-CoV Spike (S) Nanoparticle Vaccine Russell P. Wilson Senior Vice President, Business Development Vaccine World MENA & CIS 2014 Istanbul, Turkey November 19, 2014 1 www.novavax.com
More informationHuman metapneumovirus (hmpv) and parainfluenza virus 3 (PIV3) vaccine (mrna-1653)
Human metapneumovirus (hmpv) and parainfluenza virus 3 (PIV3) vaccine (mrna-1653) Conference Call February 12, 2019 Flu H10N8 H7N9 Prophylactic vaccines RSV VZV CMV hmpv+piv3 Chikungunya VLP Zika VLP Cancer
More informationMA Adult Immunization Coaltion Flu Update September 28, 2016
MA Adult Immunization Coaltion Flu Update September 28, 2016 Susan M. Lett, MD, MPH Medical Director, Immunization Program Division of Epidemiology and Immunization Massachusetts Department of Public Health
More informationPlant-Derived Influenza Virus-Like Particles: A Unique Combination of Highly Effective Product and Cost-Effective Manufacturing
Plant-Derived Influenza Virus-Like Particles: A Unique Combination of Highly Effective Product and Cost-Effective Manufacturing Nathalie Charland, PhD GHSI Workshop on Public Health Emergency Medical Countermeasures
More informationTalkin Flu Mid-America Immunization Coalition August 18, William Atkinson, MD, MPH Immunization Action Coalition
Talkin Flu Mid-America Immunization Coalition August 18, 2016 William Atkinson, MD, MPH Immunization Action Coalition Disclosures William Atkinson has worked as a consultant to Merck and as a speaker for
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More informationCloudbreak. January Cidara Therapeutics
Cloudbreak January 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationGSK s Candidate Influenza A (H5N1) Virus Monovalent Vaccine
GSK s Candidate Influenza A (H5N1) Virus Monovalent Vaccine Regulatory Pathway for Licensure VRBPAC, February 29, 2012 Katalin Abraham, Director, US Regulatory Affairs GSK Biologicals GSK s Influenza Vaccines
More informationMDPH Influenza Update
Massachusetts Department of Public Health Bureau of Infectious Disease and Laboratory Sciences MDPH Influenza Update 9-27-2017 Susan M. Lett, MD, MPH Medical Director, Immunization Program MA Department
More informationVaccine Innovation and Adult Immunization Landscape
Vaccine Innovation and Adult Immunization Landscape National Adult and Influenza Immunization Summit, May 12-14, 2015 Phyllis Arthur Senior Director Vaccines, Immunotherapeutics & Diagnostics Policy parthur@bio.org
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationCloudbreak. March Cidara Therapeutics
Cloudbreak March 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationIncorporating virologic data into seasonal and pandemic influenza vaccines
Incorporating virologic data into seasonal and pandemic influenza vaccines Kanta Subbarao WHO Collaborating Centre for Reference and Research on Influenza & Department of Microbiology and Immunology, University
More informationNeedham Healthcare Conference
UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES Needham Healthcare Conference March 2018 Safe Harbor This presentation contains forward-looking statements about Vaxart Inc. (f/k//a Aviragen Therapeutics,
More informationNovavax: Big Potential for Fast Gains
Novavax: Big Potential for Fast Gains Novavax, Inc. (NASDAQ: NVAX) is a clinical-stage small vaccine maker which focuses on recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines
More informationInfluenza: Wrap- Up and Preview of the Upcoming Season. October 6, 2016 Anita Valiani, MPH
Influenza: 2015-2016 Wrap- Up and Preview of the Upcoming Season October 6, 2016 Anita Valiani, MPH Anita.valiani@dhhs.nc.gov NC SHARPPS Surveillance for Healthcare-Associated Infections and Resistant
More informationNC IMMUNIZATION COALITION FLU THEN AND NOW NC DHHS COMMUNICABLE DISEASE BRANCH ANITA VALIANI, MPH AUGUST 1, 2018
NC IMMUNIZATION COALITION FLU THEN AND NOW NC DHHS COMMUNICABLE DISEASE BRANCH ANITA VALIANI, MPH AUGUST 1, 2018 OBJECTIVES I. 2017-18 Influenza Season Recap of the season nationally Influenza Burden Estimates
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationFluzone High-Dose Vaccine and FIM12 Efficacy Trial Results
Fluzone High-Dose Vaccine and FIM12 Efficacy Trial Results Corey A. Robertson, MD, MPH Director, Scientific and Medical Affairs, Sanofi Pasteur 1 Older Adults Suffer Disproportionately from Influenza-related
More informationInfluenza Prevention Update
Influenza Prevention Update Dean A. Blumberg, MD, FAAP Disclosure speakers bureau: sanofi pasteur, Merck Discussion off label use of FDA approved vaccines Influenza Prevention Update Seasonal influenza
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationUpdate on influenza monitoring and vaccine development
Update on influenza monitoring and vaccine development Annette Fox WHO Collaborating Centre for Reference and Research on Influenza at The Peter Doherty Institute for Infection and Immunity 1 Outline Why
More informationInfluenza Update. Lisa Grohskopf, MD, MPH Influenza Division, CDC. NAICP Call 6 October 2015
Influenza Update Lisa Grohskopf, MD, MPH Influenza Division, CDC NAICP Call 6 October 2015 National Center for Immunization and Respiratory Diseases Influenza Division Overview Surveillance update ACIP
More informationTAKEDA VACCINES INNOVATION FOR GLOBAL IMPACT. RAJEEV VENKAYYA, MD President, Global Vaccine Business Unit
TAKEDA VACCINES INNOVATION FOR GLOBAL IMPACT RAJEEV VENKAYYA, MD President, Global Vaccine Business Unit OUR MISSION Develop and deliver innovative vaccines that tackle the toughest problems in public
More informationFlu Vaccine Access Via Pharmacy Vaccine Network
Re: Flu Vaccine Access Via Pharmacy Vaccine Network Effective 9/15/2016, IEHP Medi-Cal and Medicare DualChoice Cal MediConnect (IEHP Direct) Members who are over 18 years old may obtain Flu Vaccines through
More information10/6/2014. INFLUENZA: Why Should We Take The Vaccine? OUTLINE INFLUNZA VIRUS INFLUENZA VIRUS INFLUENZA VIRUS
INFLUENZA: Why Should We Take The Vaccine? Baptist Hospital Baptist Children s Hospital Doctors Hospital J. Milton Gaviria, MD, FACP October 17, 2014 Homestead Hospital Mariners Hospital Baptist Cardiac
More informationPresentation to 2019 JP Morgan Healthcare Conference
For immediate release 10 January 2019 Presentation to 2019 JP Morgan Healthcare Conference Please find attached CSL Limited s presentation at the 2019 JP Morgan Healthcare Conference. For further information,
More informationHAI and NAI as Correlates of Protection After Influenza Vaccination
HAI and NAI as Correlates of Protection After Influenza Vaccination Arnold S. Monto Thomas Francis Jr. Professor University of Michigan School of Public Health Ann Arbor, Michigan Having Correlates is
More informationMedia Contacts: Kelley Dougherty Investor Contact: Graeme Bell (215) (908)
News Release Media Contacts: Kelley Dougherty Investor Contact: Graeme Bell (215) 652-0059 (908) 423-5185 Janet Skidmore (267) 305-7715 Merck Launches National Advertising Campaign for GARDASIL, Merck's
More informationSeasonal Influenza Report
Key findings for the 2017 2018 flu season Seasonal Influenza Report 2017 2018 Influenza activity is widely circulating in California. As of week 52 (December 24 30, 2017), the statewide geographic distribution
More informationINFLUENZA UPDATE MCAAP Webinar Susan M. Lett, MD, MPH Medical Director, Immunization Program MA Department of Public Health
INFLUENZA UPDATE 2018-2019 MCAAP Webinar 11-15-18 Susan M. Lett, MD, MPH Medical Director, Immunization Program MA Department of Public Health Presenter Disclosure Information I, Susan Lett, have been
More informationAdult Immunization Update 2015
Adult Immunization Update 2015 Objectives Upon completion of this session, the pharmacist should be able to: Compare and contrast previous versions of the ACIP immunization schedules with the most recent
More informationTransforming The Approach to Vaccines and Protein- Based Therapeutics. Alain Doucet, Ph.D. Manager, Process Development, Medicago
Transforming The Approach to Vaccines and Protein- Based Therapeutics Alain Doucet, Ph.D. Manager, Process Development, Medicago 2018-08-15 1 Medicago Overview 2 Novel Technologies 3 Robust Pipeline 2
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationUpdate on Influenza Vaccines, the Influenza Season, and the Impact of Vaccination on Influenza Disease Burden
National Center for Immunization & Respiratory Diseases Update on Influenza Vaccines, the 2017 2018 Influenza Season, and the Impact of Vaccination on Influenza Disease Burden Melissa Rolfes, PhD MPH Epidemiologist
More informationIndustry Perspective: Strategies and costs associated with increasing seasonal influenza vaccine. since 2006
Industry Perspective: Strategies and costs associated with increasing seasonal influenza vaccine use from high to low income countries since 2006 Dr. Michael Watson, sanofi-pasteur on behalf of WHO GAP
More informationMin Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention. June 18, 2015 NIBSC
Workshop on Immunoassay Standardization for Universal Flu Vaccines Min Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention June 18, 2015 NIBSC 1 Multiple Immune Mechanisms Contribute
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More information24 26 January 2013, Hong Kong SAR, CHINA. TITLE from VIEW and SLIDE MASTER February 27, 2013
The first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses 24 26 January 2013, Hong Kong SAR, CHINA 1 TITLE
More informationMaternal influenza immunisation
Maternal influenza immunisation Cheryl Cohen Centre Head Centre for Respiratory Disease and Meningitis, National Institute for Communicable Diseases cherylc@nicd.ac.za Global causes of death in children
More informationHemagglutinin Neuraminidase
Evolving Vaccine Guidance: Influenza, Meningococcal & HPV Vaccines H. Cody Meissner, M.D. Professor of Pediatrics Tufts University School of Medicine Maine Chapter AAP Bar Harbor, Maine October 16, 2016
More informationCorporate Presentation January 2019
Corporate Presentation January 2019 1 Forward-Looking Statement Disclosure Any statements made in this presentation relating to future financial or business performance, conditions, plans, prospects, trends,
More informationQuestions and Answers
Questions and Answers Recommended composition of influenza virus vaccines for use in the southern hemisphere 2016 influenza season and development of candidate vaccine viruses for pandemic preparedness
More informationSituation Update Pandemic (H1N1) August 2009
Situation Update Pandemic (H1N1) 2009 31 August 2009 Timeline pandemic (H1N1) 2009 April 12: an outbreak of influenza-like illness in Veracruz, Mexico reported to WHO April 15-17: two cases of the new
More informationMaternal Immunization: Unique considerations of public health value of vaccines given to pregnant women
Maternal Immunization: Unique considerations of public health value of vaccines given to pregnant women Estimating the full public health value of vaccines Kathleen M. Neuzil, MD, MPH Professor of Medicine
More informationThe story of modern vaccines begins in 1749, when Dr. Edward Jenner observed that milkmaids exposed to cowpox later subsequently not contract
1 The story of modern vaccines begins in 1749, when Dr. Edward Jenner observed that milkmaids exposed to cowpox later subsequently not contract smallpox. Dr. Jenner used fluids from a cow s blisters to
More informationhvivo plc ( hvivo or the Company )
hvivo plc ( hvivo or the Company ) hvivo reports positive results from the Phase IIb field study of FLU-v (FLU-v 003) representing a significant advance in the management of influenza disease Primary and
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationNew Vaccine Schedules. Disclosure. Overview. Immunization Recommendations in Primary Care. Objectives Pharmacists. Objectives Pharmacy Technicians
Disclosure Immunization Recommendations in Primary Care I have nothing to disclose. Betsy Blake, PharmD, BCPS October 2017 Objectives Pharmacists Learning Objectives: At the completion of this activity,
More informationVaccines: Poised To Deliver Significant Growth in Emerging Markets
Vaccines: Poised To Deliver Significant Growth in Emerging Markets 4 th DVFA Symposium Life Science Pierre Morgon Vice-President, Franchise & Global Marketing Operations, Sanofi Pasteur Frankfurt, May
More informationAmicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018
Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018 Introduction 2 Safe Harbor This presentation contains "forward-looking statements"
More informationCommunity and Hospital Surveillance
6SSN 2324-497 Community and Hospital Surveillance ILI, SARI, Influenza and Respiratory Pathogens 217 Influenza Season, Week 3, ending 3 July 217 SUMMARY Influenza-like illness (ILI) consultation rates
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
Committed to Transforming the Treatment Paradigm for Migraine Prevention 36th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation and the accompanying
More informationThe Expanding Rotavirus Vaccine Landscape: Lessons learned from Influenza Vaccines
The Expanding Rotavirus Vaccine Landscape: Lessons learned from Influenza Vaccines Kathleen Neuzil, MD, MPH Director, Center for Vaccine Development University of Maryland School of Medicine September
More informationSeasonal Influenza Report
Key findings for the 2017 2018 flu season October 1 st, 2017 (CDC Disease Week 40) marked the beginning of the 2017 2018 influenza season. Influenza activity is increasing in California. As of November
More informationInfluenza: The past, the present, the (future) pandemic
Influenza: The past, the present, the (future) pandemic Kristin Butler, MLS (ASCP) cm Department of Clinical Laboratory Sciences Louisiana Health Sciences Center - Shreveport Fall 2017 Objectives 1) Detail
More informationSAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018
SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018 SAFE HARBOR STATEMENT Savara Inc. ( Savara or the Company ) cautions you that statements in this presentation that are not a description of historical
More informationShabir A. Madhi. Global Overview of Maternal Immunisation
Shabir A. Madhi Global Overview of Maternal Immunisation National Institute for Communicable Diseases & University of Witwatersrand, South Africa Respiratory and Meningeal Pathogens Research Unit, & DST/NRF:
More informationCalliditas Therapeutics Q2 Report Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Calliditas Therapeutics Q2 Report 2018 Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation may contain certain
More informationFDA Approved Recombinant Hemagglutinin Influenza Vaccine Protects Against Drift Influenza Viruses
FDA Approved Recombinant Hemagglutinin Influenza Vaccine Protects Against Drift Influenza Viruses 2 nd International conference on Flu October 31- November 02, 2016 San Francisco, California, USA Protein
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationFinancing Influenza Vaccine R&D
Financing Influenza Vaccine R&D WHO GAP-II Geneve, Switzerland July 13, 2011 Robin Robinson, Ph.D. Deputy Assistant Secretary & Director HHS/ASPR/BARDA 0 Vaccine Development is Risky, Lengthy, & Expensive
More informationImmunization Update 2016 Clinical Learning Day. Tamara Sheffield, MD, MPA, MPH
Immunization Update 2016 Clinical Learning Day Tamara Sheffield, MD, MPA, MPH Disclosure I do not have any relevant financial relationships with any commercial interests I am a Medical Director employed
More informationInfluenza Virus. Influenza A virus. Influenza B virus. Influenza C virus
Outline Influenza Virus Population Data Vaccination Rates 2010-11 Influenza Vaccines Live Attenuated Influenza Vaccine (LAIV) High-Dose Trivalent Inactivated Vaccine (HD TIV) Influenza Virus Influenza
More informationTowards a Sustainable Global Infrastructure for Medical Countermeasures
Towards a Sustainable Global Infrastructure for Medical Countermeasures Institute of Medicine The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from
More informationInfluenza Vaccination Market Research Report Global Forecast till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/1621 Influenza Vaccination Market Research Report Global Forecast till 2023 Report / Search Code: MRFR/HC/1090-HCRR
More informationMedicago: transforming the approach to vaccines and protein-based therapeutics. Bruce D. Clark PhD President & CEO September 27, 2017
Medicago: transforming the approach to vaccines and protein-based therapeutics Bruce D. Clark PhD President & CEO September 27, 2017 Medicago Overview Focus Manufacturing technology Vaccine technology
More informationCorporate Presentation Fourth Quarter 2017
Corporate Presentation Fourth Quarter 2017 November 2017 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationCell Therapy. Cytori Corporate Presentation January 2012
Cytori Corporate Presentation January 2012 Safe Harbor This presentation may contain certain forward-looking statements. All statements, other than statements of historical fact, that address activities,
More informationDeveloping a novel Group B Streptococcus (GBS) Vaccine. Patrick Tippoo
Developing a novel Group B Streptococcus (GBS) Vaccine Patrick Tippoo Presentation 1. Overview of Biovac 2. GBS Project Overview 3. African Significance Biovac Overview A Centre of Excellence rooted in
More informationAn Affordable Pandemic Influenza Vaccine Solution for Developing Countries (and Developed Countries Too)
An Affordable Pandemic Influenza Vaccine Solution for Developing Countries (and Developed Countries Too) James M. Robinson, PE VP Technical and Quality Operations Novavax, Inc. New Cells for New Vaccines
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationGSK s Adjuvanted Influenza Vaccines The Taming of the Flu
GSK s Adjuvanted Influenza Vaccines The Taming of the Flu JITMM, Bangkok, October 2008 Bruce L. Innis, MD Global Clinical Research and Development GlaxoSmithKline Biologicals 1 Annual Burden of Influenza
More informationUtrophin Modulation: A Universal Treatment Approach to DMD. End Duchenne Tour April 2018
Utrophin Modulation: A Universal Treatment Approach to DMD April 2018 Legal Disclaimer Statements in this presentation, other than statements of historical fact, constitute forward-looking statements within
More informationSeasonal Influenza Report
Key findings for the 2017 2018 flu season Seasonal Influenza Report 2017 2018 Influenza activity remains elevated throughout California. As of 2018 week 9 (February 25 March 3, 2018), the statewide geographic
More informationPROMISE 2 Top-Line Data Results January 8, 2018
PROMISE 2 Top-Line Data Results January 8, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking statements within the meaning of Section 27A
More informationInfluenza vaccine-it s complicated. Mark H. Sawyer MD UCSD School of Medicine and Rady Children s Hospital San Diego
Influenza vaccine-it s complicated Mark H. Sawyer MD UCSD School of Medicine and Rady Children s Hospital San Diego Objectives Explain how new strains of influenza virus are created so that you understand
More informationValneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth
Valneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth Strong sales performance in 2017 (unaudited) Total revenues of 109.8 million in 2017 (2016-97.9 million) representing year-on-year
More informationImmunizations: An Overview. Sutter Health May 9, 2017 John Apostolo, PharmD, MBA Heidi Rens, PharmD
Immunizations: An Overview Sutter Health May 9, 2017 John Apostolo, PharmD, MBA Heidi Rens, PharmD Sutter Health: System Overview 2 Agenda Sutter Health Overview Sutter Health Vaccine overview Clinical
More informationREFERENCE CODE GDHC1161DFR PUBLICAT ION DATE SEPTEMBER 2013 MENOMUNE (MENINGOCOCCAL VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC1161DFR PUBLICAT ION DATE SEPTEMBER 2013 MENOMUNE (MENINGOCOCCAL VACCINES) - Executive Summary Menomune: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US 5EU
More informationPROMISE 1 Top-Line Data Results. June 27, 2017
PROMISE 1 Top-Line Data Results dd June 27, 2017 Forward Looking Statements This presentation and the accompanying commentary contains certain forward-looking statements within the meaning of Section 27A
More informationPotential public health impact of RSV vaccines. R. Karron December 2016
Potential public health impact of RSV vaccines R. Karron December 2016 1. RSV is The leading cause of hospitalization in infants and in many high-income countries; >2 million medical visits annually in
More informationInfluenza Vaccines: Giving the Right Dose at the Right Time. Agenda
Influenza Vaccines: Giving the Right Dose at the Right Time Wednesday, December 9, 2015 12:00 PM ET Agenda Agenda Welcome and Introduction William Schaffner, MD, NFID Medical Director Influenza Vaccines:
More informationImmunization Update 2017 Adult Clinical Learning Day. Tamara Sheffield, MD, MPA, MPH
Immunization Update 2017 Adult Clinical Learning Day Tamara Sheffield, MD, MPA, MPH Highlighted Topics Influenza Vaccine Errors 2 Dose HPV Community protection Tdap in pregnancy Meningococcal Future Recs
More informationUpdate on production of plant-made influenza Virus-Like Particle (VLP) vaccine
Update on production of plant-made influenza Virus-Like Particle (VLP) vaccine January 25th 2013 Nathalie Landry Vice President of Product Development TSX: MDG OTCQX: MDCGF Forward-Looking Statements and
More informationTheravance Biopharma, Inc. (NASDAQ: TBPH)
Theravance Biopharma, Inc. (NASDAQ: TBPH) FDA Approval of YUPELRI TM (revefenacin) Inhalation Solution November 9, 2018 THERAVANCE and the Cross/Star logo are registered trademarks of the Theravance Biopharma
More informationForward Looking Statements
Antiviral Therapies Forward Looking Statements This presentation contains forward-looking statements, including the timing of our drug development programs. Risks include delays in manufacturing created
More informationAdvisory Committee on Immunization Practices Meeting Update
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Advisory Committee on Immunization Practices Meeting Update June 2017 JoEllen Wolicki, BSN, RN Nurse
More informationOutline. Summary of 2017 season; vaccine coverage and effectiveness. Influenza A/H3 vaccine problems season new vaccines and programs
Influenza Allen Cheng Professor of Infectious Diseases Epidemiology, Monash University Director, Infection Prevention and Healthcare Epidemiology Unit, Alfred Health Outline Summary of 2017 season; vaccine
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationNovartis receives FDA approval of Menveo, a vaccine to prevent meningococcal disease
Novartis Vaccines and Diagnostics, Inc 350 Massachusetts Avenue Cambridge, MA 02139 http://www.novartisvaccines.com MEDIA RELEASE MEDIA RELEASE MEDIA RELEASE Novartis receives FDA approval of Menveo, a
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationInnovation In Ophthalmics
Innovation In Ophthalmics Ophthalmic Innovation Summit @ AAO 2018 October 25, 2018 Mark Iwicki Chairman & CEO, Kala Pharmaceuticals Disclaimers and Notices This presentation contains forward-looking statements
More informationTransforming Treatment for Migraine. 16 th Annual Needham Healthcare Conference April 4, 2017
Transforming Treatment for Migraine 16 th Annual Needham Healthcare Conference April 4, 2017 Forward Looking Statements This presentation and the accompanying commentary contain certain forward-looking
More informationREFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Gardasil: Key Metrics in Nine Major
More informationSummary: Low and Decreasing Activity
Manitoba Health, Seniors and Active Living (MHSAL) Influenza Surveillance Report `Week 2017 2018 53: Dec 28, 2014 Jan 3, 2015 Summary: Low and Decreasing Activity Week 16 17 (Apr. 15 28, 2018) Data extracted
More information